Our winning team

We are a multi-disciplinary R&D team of biologists, chemists, clinicians, engineers, computer technicians, lab professionals, biostatisticians, supported by so many more, all working tirelessly towards one goal; to improve the healthcare outcomes of people afflicted with serious diseases.

Our team

Our team

All Our departments support our business and our stakeholders

Is composed of 20 different nationalities, 65% university graduates, and 18% PhD’s. Over 60% are women and our employees together speak 15 languages.

In addition to our clinical, regulatory, R&D, manufacturing departments we are supported by a superb and dedicated team of legal, logistical, finance and administrative experts, all striving to make their families proud of the work they do to improve the healthcare outcomes for people afflicted with serious conditions.

Our finance department supports our business.

All Our departments support our business and our stakeholders

Passionate about what we do

“What I am most proud of is my team and what they have achieved together. It’s an amazing success to get a drug approved in one major jurisdiction such as FDA for the United States or EMA for Europe or PMDA in Japan. This team has obtained five such approvals so far.”

Luis Mora, Managing Director



PharmaMar team today

A team of 400+ professionals worldwide

About three-quarters are in Spain, with the rest spread over our six other country offices, five in Europe plus the United States.

PharmaMar’s values, which we are all accountable to, are hope and responsibility to patients, our uniqueness in approach, our commitment and rigor to the science and our project, and respect for our stakeholders: patients, providers, partners, people, the planet and shareholders.

Our success is testimony to the dedication and effort PharmaMar’s team brings to work every day, striving to make their families proud of the work they do to improve healthcare outcomes for patients.

Our Senior Management

President, Chief Executive Officer and Chairman of the Board

D. José María Fernández Sousa-Faro, Ph.D.

Fun fact: "I have scuba dived in over 25 countries"

José María founded PharmaMar in 1986 and is currently the Chairman of the Board of Directors and Executive President. He has been a Professor of Biochemistry at the Complutense University of Madrid and the University of Santiago de Compostela, he obtained an MBA from the IESE Business School in Madrid. Dr. Fernández Sousa-Faro has over 90 scientific articles and patents in the field of biochemistry, drug discovery and molecular biology. With more than 35 years of experience in the pharmaceutical industry, he has held positions within the executive management of ICI-Farma, Antibióticos, Zeltia and PharmaMar. He was a member of the Board of Directors of Antibiotics, Penibérica, Biolys, ICI-Farma, Pescanova, Transfesa, Cooper–Zeltia, ICI-Zeltia and Banco Guipuzcoano.

Managing Director, Oncology & Virology Business Units

Luis Mora Capitán

Fun fact: "I explore new routes on my mountain bike whenever I can"

With 30 years’ experience in the pharmaceutical industry and a Degree in Business Administration from the University of Barcelona, Luis Mora began his career as the Financial Controller for Zambon, S.A. and Pharmazam, S.A. in Barcelona and later as Head of Finance for Zambón Portugal. From 1995-2000 he served as Financial Controller with the Antibióticos Group (Montedison), and as Board Member of Vitatene, in Milan, Italy. He joined PharmaMar in 2000 as Chief Financial Officer and was appointed Managing Director in 2008, presiding over the unit through Yondelis®, Aplidin® and ZepzelcaTM approvals in various countries including those regulated by FDA and EMA.

Chief Financial Officer

María Luisa de Francia Caballero

Fun fact: "When I am not in the office you might probably find me hiking the mountains. I love being outdoors when I can relax"

Ms. de Francia has been with PharmaMar and its predecessor Zeltia since 1988 holding various positions in the finance department, and becoming the Chief Financial Officer of Zeltia in 2000, and then for PharmaMar since the PharmaMar-Zeltia merger in 2015. Ms. de Francia holds an undergraduate degree in law, as well as a graduate degree in Business Administration from the Universidad Pontifical Comillas (ICADE) de Madrid. She also is a member of the Board of Directors for GENOMICA subsidiary.

General Counsel and Secretary of the Board of Directors

Juan Gómez Pulido

Fun fact: "Instead of the job I have, I've always dreamed of being an airplane pilot"

Juan Gómez Pulido is currently General Counsel and Secretary of the Board of Directors of PharmaMar, being responsible for all the company’s corporate legal matters, since July 2019. Since joining Zeltia in January 2013, and later in PharmaMar, he has been Senior Legal Counsel of the Legal Department of the Group. Previously, Mr. Gómez Pulido was a Senior Associate of the Corporate and M&A Department of Ramón y Cajal Abogados, a Madrid-based law firm, as well as an Associate of the corporate department of other national and international law firms. Mr. Gómez Pulido holds a Law Degree from the Pontificia University of Comillas (ICADE E-1) and a Master’s Degree in Corporate Law from IE Business School.

Global Compliance Head

Sandra Llamera Sánchez

Fun fact: "Passion for nature and the mountains of León, my hometown, especially in winter when I can enjoy a good day of skiing. And of course, as soundtrack, Queen and The Rolling Stones!"

Sandra Llamera joined PharmaMar as Global Compliance Head in 2020, after a detailed experience in the pharma industry. Since 2018, she has been a member of the Board of Directors of the Institute of Compliance Officers, starting while at Teva as Director of Compliance for Spain/Portugal. She implemented the compliance programs at the factory and logistics center in Spain, led the adaptation to the new European Data Protection Regulation (GDPR), and actively participated in the design and implementation of the global compliance program imposed by the US Department of Justice. Sandra began her career at Pfizer, serving in both the legal and compliance departments amongst others, for 12 years. She was involved in anti-corruption policies, FCPA regulations, clinical trial monitoring, drug promotion policies, competitive practices and audits, among others She has a degree in Law from the San Paulo CEU University and has been a speaker at various professional courses and conferences.

Director, Capital Markets & Investors Relations

José Luis Moreno Martínez-Losa

Fun fact: "When not talking about cash flows I like to flow on powder with my skis or flow downhill with my bike"

Mr. Moreno has been the Director of Capital Markets and Investor Relations at PharmaMar since 2009. From 2002 until 2009, he was the co-founder and managing partner of the independent financial group Solventis. He previously headed equity sales at Banco Espirito Santo Investment for three years after holding the same position at Benito y Monjardín SVB. He started his career in 1994 working in the research and marketing department of the Spanish Futures and Options Exchange developing financial derivatives. Mr. Moreno graduated with a degree in Management and Business Administration from the University of Hertfordshire and has a degree in Business Administration from the University of Barcelona. He has an executive management program (PDG) from IESE and is also a Chartered Alternative Investment Analyst (CAIA). He has taught Masters courses on financial derivative products offered by the University of Barcelona, as well as other related courses at the Abat Oliba CEU University, the Center for Financial Studies and MEFF.

Director, Quality Unit

José Luis Ortega Conejero

Fun fact: "In my spare time, I love riding my motorbikes, and taking my dogs for a run"

José Luis received his Master’s degree in Biochemistry from the Complutense University of Madrid. He has experience in Quality related issues since 1986 and, in particular, in different management positions within the pharmaceutical industry since 1990 (for example Bristol-Myers, DSM Deretil and Justesa Imagen S.A). He is also an expert in DuPont’sTM STOP® safety methodology. He has worked at the Spanish National Accreditation Body (ENAC), and as a Quality consultant. He joined PharmaMar in 2004 as the Director of the Quality Unit. He oversees and manages all aspects of GxP Quality Functions.

Legal Director - Business

María Concepción Sanz

Fun fact: "If I were born again, I would have chosen to be a veterinarian. It's a little late now!"

Ms. Sanz is currently Director of the business area in the Legal Department of PharmaMar, a position she has held since July 2019. Ms. Sanz joined PharmaMar in 2007 as Legal Advisor, and in 2015 she was appointed as vice-secretary of the Board of Directors at PharmaMar. Previously, she was an Associate at the Elzaburu law firm. Ms. Sanz has a Law Degree from the Pontificia University of Comillas (ICADE E-1) and a Master’s Degree in Intellectual Property (Magister Lvcentinvs) from the University of Alicante.

Internal Auditor

Juan Carlos Villalón Gómez

Fun fact: "I like to play all kinds of sports. I even won a slam dunk contest when I was young playing basketball"

With a Master’s in Financial Management from ESIC, he joined the PharmaMar Group’s Finance team in May 1989. Since November 2011, he has been in charge of the Group’s Internal Audit department, supervising the internal control system for financial reporting. He was previously Chief Accountant at Zeltia (June 2002–Nov. 2011) and at PharmaMar (Nov. 1994-June 2002), also collaborating with the Group’s other subsidiaries.

Management Team Pharmamar

Global Head of Regulatory Affairs

María José Arce-Tomas, Ph.D.

Fun fact: “I had dinner with Monty Python´s co-founder and star John Cleese”

María joined PharmaMar in November 2019 from Novo Nordisk A/S where she was the Corporate Global Vice President and Head of Biopharm Global Regulatory Affairs. Prior to Novo Nordisk, María held a number of senior corporate leadership positions at GE Healthcare, GSK, Abbott, Takeda and Norgine. María holds a PhD in Biochemistry from King’s College, University of London, an MSc in Toxicology and a BSc in Pharmacy from Valencia University in Spain. She also has a Postgraduate Diploma in Regulatory Affairs from the University of Cardiff. At PharmaMar, Maria is the face of the Company to the regulatory authorities around the world. She works side by side with the senior executive leadership team from R&D, Commercial, Legal, Business Development and Operations and externally with Regulators and other experts, to deliver on Global business strategies and maximize the products’ potential in an effective and compliant manner.

Chief Operating Officer of Pharmamar U.S.

Pascal Besman

Fun fact: “Prior to working on Wall Street, I was a professional pianist”

Pascal Besman oversees all activities of PharmaMar in the United States, including alliance management with Jazz Pharma. Mr. Besman joined PharmaMar from Maxim Group in 2016, a New York-based global investment bank, where he served as Head of Healthcare Equity Sales since 2014. Prior, he served as a health care specialist and institutional equity salesperson at several leading investment banks, including JMP Securities, UBS, Bear Stearns, Lehman Brothers and Merrill Lynch, catering to institutional healthcare investors. He authored for many years a widely-read weekly biotech overview newsletter for C-suite executives entitled The Buzz. He also is a published novelist. Mr. Besman holds a B.Sc. from the London School of Economics.

Director of Public Affairs

Elisa Borrego, Ph.D.

Fun fact: “I love playing paddle tennis and my goal is to win, at least once, a local tournament”

Elisa joined PharmaMar in 2021. She holds a PhD in Pharmacy from UCM; a Master's degree in Public Health and Health Institutions, both from UAM; and an Executive MBA from IE. With more than 25 years of experience in the healthcare sector, she has worked in both the public and private sectors. Since 2015, she led the Access and Government Affairs teams at Bristol-Myers Squibb, where she led the launch of 11 products in less than two years, with a special focus on immuno-oncology. In the private sector, she has also held positions of responsibility at Sanitas Hospitales, Lilly and MSD. In her time in public management, she has been General Director of Quality, Accreditation, Evaluation and Health Inspection of the Community of Madrid and Managing Director of PC. Elisa has great negotiating skills and is a promoter of unique and innovative ideas and projects.

Director, Finance Oncology Business Unit

Elena Calleja Crespo

Fun fact: “If I ever get lost you will find me in Cantabria enjoying its mountains, coasts and gastronomy”

Elena obtained her degree in economics, with a focus on the Public Sector and Monetary Economy, from the Complutense University of Madrid and a master in Corporate Tax Consultancy from ICADE University. She started her professional career at PriceWaterhouse in Madrid in the Audit division and then moved to the Tax, Legal and Financial Division, where she worked until 1994. She was a Senior Consultant in C&G, where she managed tax consultancy and financial projects in various companies, both public and private, within the logistics, transport and technological research sectors. In 1998, she returned to PricewaterhouseCoopers Madrid as Consultant within the Tax, Legal and Financial Division to various global financial sector clients. She joined PharmaMar in 2002 as the Financial Comptroller., a position she held until she was appointed Finance Director in April 2008.

Director, Reseach & Development

Carmen Cuevas Marchante, Ph.D.

Fun fact: “In my job I explore the sea, in my free time I like to discover new paths by hiking or cycling”

Carmen joined PharmaMar in 1997 performing in different positions in the R&D Department. In 2003, she was appointed Director of Research & Development at PharmaMar, where she is responsible for the areas of drug discovery, medicinal chemistry and preclinical. Carmen has authored more than 85 scientific publications and has been invited to speak numerous times at international scientific congresses and research institutions. She has an impressive record in drug discovery, with over 20 patent applications and more than 20 funded research programs. Among other achievements, she is responsible for the development of the innovative synthesis process of the marine-derived anticancer drug, Yondelis. Carmen obtained her Ph.D. in Chemistry from the University of the Basque Country, and completed her post-doctoral training at the School of Medicine at the University of Alcala de Henares in Madrid, working within the Pharmacology Department. She also obtained a management development program diploma from IESE.

Director, Project Coordination

Carmen Eibe

Fun fact: “I am passionate about new technologies, from the use of Artificial Intelligence to invest in the stock market, through the different business models of electric cars to the ironing robot that also folds and organizes clothes”

Ms. Eibe graduated in Economics and Business Administration from the University of Seville, and holds an executive MBA from the School of Business Administration (EAE). She joined the Zeltia Group in 2003 where she leads the Department of Project Coordination that manages numerous R+D+I projects, in which PharmaMar and the Group's subsidiaries participate. Recently she was an executive member of the Boards of EuropaBio, European Biopharmaceutical Enterprises (EBE-EFPIA) and Vice-president at the Spanish Biotechnology Association (ASEBIO) representing PharmaMar. Previously, since 1998 she was General Secretary of the Chamber of Commerce of Spain in Belgium and Luxembourg, having climbed since 1994 through various positions within the Commercial Department. During her tenure as head of the Chamber in Brussels, she was appointed General Secretary of the Federation of Spanish Chambers of Commerce in Europe (FEDECOM).

VP Global Head Virus & Inflammation

José María Jimeno, M.D. Ph.D.

Fun fact: “Mountain climbing makes me fun, happy and motivated”

Dr. Jimeno rejoined PharmaMar in 2020 in the virology unit. He is a medical oncologist, and holds a PhD from the University of Barcelona. From 2015, Dr. Jimeno served as Chief Medical Officer at Phosplatin Therapeutics, and remains part of its Scientific Advisory. He was formerly VP of Clinical and Scientific Development at PharmaMar, responsible for developing Yondelis®, which is approved in over 80 countries including the US and EU, and the development of Aplidin® which is approved in Australia for multiple myeloma. Previously he worked at Farmitalia Carlo Erba and US Biosciences. Most recently, Dr Jimeno was co-founder and CEO of Pangaea Biotech, a cancer diagnostics company where he was involved in developing their EGFR diagnostic approved by the FDA. Dr. Jimeno has published over 100 papers in peer review journals on cancer and is a guest lecturer in immunology at The University of Zaragoza in Spain.

Director International Marketing and Sales

Juan Nogués Ortuño

Fun fact: “I was... and I like to think I still am, a rugby player"

Juan joined PharmaMar in 2012 and, since 2013, he has been responsible for the International Marketing and Sales Department, for the progress of Yondelis® sales in Spain and Portugal, and in PharmaMar's European subsidiaries (Italy, Germany, France, Switzerland, Austria and Benelux). He also coordinates relations with IMMEDICA (Nordic and Central European countries) and GENESIS PHARMA (Greece, Cyprus and Croatia), which sell Yondelis® under license in other European countries. A graduate in Law and Economics from ICADE (E-3) and PADE from IESE, he has more than 35 years' experience in the pharmaceutical industry. Before working at PharmaMar Juan was General Manager at the Spanish subsidiary of EISAI and responsible for Hospitals and Oncology at GSK.

VP, Business Development & Licensing

Heiner Pieper

Fun fact: “In my free time I like watersports, and also to kick sports cars around the Nürburgring”

Heiner graduated in Economics and Business Administration from the University of Cologne, and started his pharmaceutical career at Bayer. His experience spans over 25 years in commercial functions in Europe and Latin America. He has also worked for ASTA Medica AG and Baxter as country manager in Argentina and regional director for Latin America where he led Oncology for key brands such as Navelbine® and Holoxan®. In 2003, he joined Merck KGaA’s headquarters in Darmstadt, where he became the regional director for Latin America and launched Erbitux® within the Oncology franchise. With the acquisition of Serono in 2007 he moved to business development in Geneva and headed MerckSerono’s global department for emerging markets and general medicine before joining PharmaMar in 2013 as VP, BD&L. He is a member of the Pharmaceutical Licensing Club in Germany (PLCD) and part of the European network of Pharmaceutical Licensing groups (EPLG).

Director, Human Resources and IT

Luis Rupérez Cuenca

Fun fact: "I am passionate about Menorca, I keep discovering new corners of its coast by kayaking"

Luis Rupérez has been Director of Human Resources, Occupational Risk Prevention, Environment, Information Technology and General Services for PharmaMar Oncology Spain and its subsidiaries in Europe and the US since he joined in 2003. He has a degree in Psychology from the Complutense University of Madrid. Marketing and Commercial Management Program and Human Resources Management Program. He has been working as Human Resources Director in the Pharmaceutical Industry since 1992. He worked at Servier Laboratories (Paris, France) and Antibioticos Farma. Previously he worked in the Human Resources area of service sector companies such as Ibermática and Sofemasa (Sema Group).

Director, Virology Business Unit

Belén Sopesén Veramendi

Fun fact: “Two deserts, two rallies: Abu Dhabi and Paracas (Peru) Different but complementary. Go for the next one!”

She joined PharmaMar in 2005 and is Virology Business Unit Director since 2021. She sits on the Board of Sylentis and is an independent Board member of Biocross SL. Previously, she was Director of Market Research and, between 2015-2018, General Manager and Board Member (2014-2018) of Xylazel. Between 2006 and 2014, she was General Manager of Noscira, a biotechnology company in the group dedicated to R&D. Previously she was Manager and Technical Director of Qualysite Consultores., a company that she co-founded. Previously, she worked in a Contract Research Organisation, Cibest between 1997 and 2001). She belongs to the Spanish Association of Pharmaceutical Medicine, of which she was president from 2013 to 2015, and for 20 years has been on the teaching committee of the Master Course in Clinical Trials Monitoring at the Madrid Professional Association of Pharmacists. She holds a PhD in Pharmacy from the Universidad Complutense de Madrid.

Comunication Director

Lara Vadillo

Fun fact: “I love to travel, but for many years I have found my source of balance in the practice of yoga.”

Lara joined PharmaMar in December 2021, having previously developed her professional career in the field of corporate communications at Grupo DIA, where she headed the Communications and External Relations Department. She has extensive experience in the Media, such as CNN+, Cuatro and Actualidad Económica, as a specialist in economic and financial information. She holds a degree in Journalism from the Universidad Complutense in Madrid, the last two years of which she studied at L'Université Paris VIII Vincennes Saint-Denis. She has also completed Management and Communication programs at the IE Business School and on the subject of the EU at the College of Europe.

Director, Clinical Development

Ali Zeaiter, M.D.

Fun fact: “I love relaxing with my tropical fish and parrot”

Ali Zeaiter joined PharmaMar in 2018 as the Director of Clinical Development in the Oncology Unit. Dr. Zeaiter is a board certified Medical Oncologist with over 15 years’ experience in pharma. Before joining PharmaMar, he was the Head of Clinical Development of the Onco-hematology therapeutics area at Servier Laboratories where he led the integration of Shire Oncology. Before that, he spent 11 years at F. Hoffmann-La Roche AG in Basel, Switzerland. In his role as Global Development Team Leader, Dr. Zeaiter led the development strategies of different projects such as Avastin (Pediatric and GBM), Tarceva and Alecensa, and was member of the Lung Disease Area Strategy of the company. Before joining Roche, between 2003 and 2007, Dr. Zeaiter served as a medical oncologist in different Parisian hospitals, also working for 2 years at the oncology-specialized CRO, Cvitkovic et Associés Consultants. Dr. Zeaiter completed his Medical Degree, followed by a Diploma of specialization in Medical Oncology at the Russian State Medical University in Moscow, receiving a Certificate of specialization in Medical Oncology from the University of Paris VII in Paris, France.

0.402 seconds.